Novo Nordisk and Pharmacia reach out-of-court settlement in human growth hormone.
The agreement will have no significant impact on Novo Nordisk's financial results. Terms of the settlement will not be disclosed.
Lars Rebien Sorensen, president and CEO of Novo Nordisk said, "We are pleased to have reached an equitable settlement with Pharmacia regarding this litigation. We have thus achieved our goal of protecting our intellectual property without adversely affecting the well-being of patients."
The Novo Nordisk growth hormone, Norditropin, was first introduced in Europe in 1988, and was later approved by the US Food and Drug Administration in 1995. Norditropin cartridge and NordiPen, the first and only premixed growth hormone for a pen, was introduced into the US market in October 2000.
Novo Nordisk is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Novo Nordisk employs approximately 14,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||patent dispute; Novo Nordisk A/S and Pharmacia Corp.|
|Comment:||Novo Nordisk and Pharmacia reach out-of-court settlement in human growth hormone.(patent dispute; Novo Nordisk A/S and Pharmacia Corp.)|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Nov 1, 2000|
|Previous Article:||Antigenics wins crucial patent battle with Stressgen.|
|Next Article:||Avitar receives approval on Oralscreen collector patent.|
|MEDAREX/ZYMOGENETICS TO DEVELOP ANTIBODY THERAPEUTICS.|
|Novo Nordisk sues Sanofi-Aventis for insulin delivery device patent infringement.|
|NORVO NORDISK FUNDS ATHN.|